The carcinoembryonic antigen cell adhesion molecule 1 (CEACAM1) is downregulated in colonic and intestinal hyperplastic lesions as well as in other cancers, where it functions as a tumor suppressor. To investigate the functions of CEACAM1 in the normal intestine and in intestinal tumors, we generated a compound knockout mouse model and examined both Ceacam1
The carcinoembryonic antigen cell adhesion molecule 1 (CEACAM1) is downregulated in colonic and intestinal hyperplastic lesions as well as in other cancers, where it functions as a tumor suppressor. To investigate the functions of CEACAM1 in the normal intestine and in intestinal tumors, we generated a compound knockout mouse model and examined both Ceacam1 À/À and Apc 1638N/ þ :Ceacam1 À/À mice. Ceacam1 À/À intestinal cells exhibited a significant decrease in apoptosis, with no change in proliferation or migration, however. Compound Apc 1638N/ þ :Ceacam1 À/À mice demonstrated an increase in intestinal tumor multiplicity and tumor progression. Increases in intussusceptions and desmoid lesions were also observed. We have shown that CEACAM1-L associates with b-catenin by co-immunoprecipitation and colocalization in CEACAM1-L-transfected CT26 and CT51 mouse colon carcinoma cells. Ceacam1 À/À enterocytes displayed decreased glycogen synthase kinase 3-b activity with corresponding nuclear localization of b-catenin. Increased T-cell factor/Lef transcriptional activity was observed in CEACAM1-null CT51 colonic cells and in Caco2 colon cancer cells in which CEACAM1 was downregulated. A significant increased expression in c-Myc and cyclin D1 targets of the Wnt signaling pathway was also revealed in the Ceacam1 À/À intestine. CEACAM1 therefore actively participates in Wnt signaling in intestinal cells and its downregulation in intestinal tissue contributes to malignancy by augmenting tumor multiplicity and progression.
Introduction
Colorectal cancer (CRC) arises from the dysregulation of the balance between proliferation, differentiation and apoptosis of normal intestinal cells that become progressively disrupted by accumulation of mutations in several signaling pathways, namely the Wnt, Ras, p53, Dcc and TGF-b pathways (Kinzler and Vogelstein, 1996) . The earliest manifestation of colorectal neoplasia is the appearance of aberrant crypt foci that progress to hyperplastic polyps, adenomas and, finally, carcinomas. A small proportion (o10%) of CRC cases are hereditary and familial adenomatous polyposis (FAP) patients have germline mutations in the adenomatous polyposis coli (APC) gene (Takayama et al., 2001; de la Chapelle, 2004) . Furthermore, over 80% of sporadic CRCs also demonstrate APC mutations (Rowan et al., 2000; Demant, 2003) . Mutations in APC cause its loss of functions, which stabilizes b-catenin followed by its nuclear translocation Morin et al., 1997) . Nuclear b-catenin then associates with various members of the T-cell factor (TCF) transcriptional activators that regulate Wnt target genes involved in cell proliferation, differentiation, migration and apoptosis Morin et al., 1997) .
Carcinoembryonic antigen cell adhesion molecule 1 (CEACAM1) is a member of the carcinoembryonic antigen (CEA) family (Beauchemin et al., 1999) . CEACAM1 is a cell adhesion molecule mediating trans-homophilic association between its first immunoglobulin (Ig) domains expressed on opposing cells (Gray-Owen and Blumberg, 2006) . CEACAM1 is expressed in epithelia, hemopoietic and endothelial cells (Gray-Owen and Blumberg, 2006) . The CEACAM1 gene produces alternatively spliced isoforms containing Ig-like domains linked to either a short 10 aa (CEACAM1-S) or long 71-73 aa (CEACAM1-L) cytoplasmic domain (Gray-Owen and Blumberg, 2006) . CEACAM1 expression is downregulated in colon tumors (Neumaier et al., 1993; Kunath et al., 1995) and several other cancers (Horst and Wagener, 2004) . CEACAM1 downregulation is an early event in the genetic progression of colon cancer. Serial analysis of gene expression comparisons and DNA chip analyses show its absence in hyperplastic lesions, intestinal microadenomas and adenomas (Nollau et al., 1997; Buckhaults et al., 2001; Notterman et al., 2001; Nittka et al., 2004) . CEACAM1 tumor suppressor activities are dependent upon the presence of its L cytoplasmic domain (Kunath et al., 1995) . In support of the role of CEACAM1-L in inhibition of tumor growth, we have recently shown that Ceacam1 À/À normal colon exhibits increased proliferation and decreased apoptosis. Upon azoxymethane carcinogenic induction, a greater number of colon tumors form in CEACAM1-deficient mice relative to littermate controls (Leung et al., 2006) . However, as both Ceacam1 and Apc loss of function represent early events in intestinal cancer development, we questioned whether deletion of the Ceacam1 gene influenced intestinal tumor progression driven by the Apc loss of function and whether both genes impacted on the same signaling pathways. The Ceacam1 À/À enterocytes or CEACAM1-devoid cells displayed decreased apoptosis, dysregulated Wnt signaling, b-catenin nuclear accumulation and enhanced TCF/ Lef transcriptional activity. Compound Apc
Ceacam1
À/À mice demonstrated an increase in intestinal tumor multiplicity and progression relative to controls. These results suggest that CEACAM1 enhances progression of intestinal cancer in an Apc-deficient background.
Results
Intestinal apoptosis is decreased in CEACAM1-deficient mice We have previously shown that structural characteristics of the Ceacam1 À/À normal colonic crypts were not altered relative to wild-type (WT) controls but that proliferation was significantly increased and apoptosis decreased (Leung et al., 2006) . To verify whether intestinal villi exhibited similar characteristics, sections of 3-month-old Ceacam1 þ / þ and Ceacam1 À/À jejunum (n ¼ 8) were stained ( Figure 1A ). Ceacam1 À/À jejunum exhibited the same length of intestinal villi and the same number of crypt cells relative to WT controls. Goblet cell differentiation was similar as judged by the periodic acid Schiff (PAS) staining ( Figure 1A ). The size of Ceacam1 À/À enterocytes was similar to that of the WT littermates. In addition, the migration of the differentiating enterocytes was not affected in the Ceacam1 À/À mice ( Figure 1B) .
Stainings with an antibody to 5 0 -bromo-2 0 -deoxyuridine (BrdU) after a 6 h in vivo labeling period (data not shown) or with an antibody to Ki67 were used to gauge proliferation of jejunal and ileal enterocytes. The Ceacam1 À/À intestinal proliferation index was similar to that of the WT mice ( Figure 1C ). CEACAM1-L regulates hepatocyte proliferation through its insulin receptor- (Poy et al., 2002a) and EGFR-mediated-Tyr phosphorylation (Abou-Rjaily et al., 2004) with consequent downregulation of the Ras-mitogen-activated protein kinase (MAPK) signaling. Hence, we monitored Erk activity by determining phospho-ERK expression in the Ceacam1 À/À normal jejunum and ileum ( Figure 1D ) and found no significant differences between the WT and CEACAM1-null mice.
Apoptosis was measured by terminal uridine deoxynucleotidyl transferase dUTP nick end labeling assays and Annexin V staining. Ceacam1 À/À mice showed a two to threefold decrease in early and late apoptosis ( Figure 1E ), as observed in CEACAM1-deficient colon (Leung et al., 2006) . We examined the status of the survival factor Akt by immunoblotting Ceacam1 À/À intestinal proteins with an anti-phospho-Akt antibody. There was no significant change in activated Akt in this tissue ( Figure 1F ). Collectively, these results indicate that a similar number of enterocytes are produced in Ceacam1 À/À crypts and that their rate of migration during differentiation is not altered compared to those of the WT mice. However, these enterocytes do not undergo programmed cell death in a timely fashion.
Intestinal tumor multiplicity and progression are increased in Apc 1638N/ þ :Ceacam1 À/À mice Systemic deletion of the Ceacam1 gene does not lead to the development of any tumors unless a carcinogenic or genetic insult is initiated (Leung et al., 2006) . However, both the human CEACAM1 and APC genes sustain a loss of function early in tumor initiation as CEACAM1 becomes downregulated or absent and APC mutated at the hyperplastic stage of colonic tumor development (Nollau et al., 1997; Nittka et al., 2004) . We questioned whether lack of CEACAM1 expression influenced Apc-driven intestinal tumor progression. We mated heterozygous C57Bl/6 Apc 1638N/ þ mice with a mutation in the endogenous Apc gene (Fodde et al., 1994) with two C57Bl/6 Ceacam1-deleted mouse lines (2D2 and 11H11; Leung et al., 2006) , thereby producing cohorts of doubly heterozygous and
mice. We crossbred the Ceacam1 À/À mice with the C57Bl/6 Apc 1638N/ þ mice rather than the well-known intestinal Apc Min mice as the former had demonstrated an increase in hyperplastic colonic lesions in addition to intestinal tumors (Fodde et al., 1994) . Results from both lines were pooled as they showed similar results. All animals were killed between 6-7 months of age. Apc 1638N/ þ mice produced on average 1.5±0.1 tumors per animal (n ¼ 94), whereas the Apc 1638N/ þ :Ceacam1 (Figure 2b ), indicating that loss of CEACAM1 expression contributed more significantly to tumor progression. Clinical pathology revealed a broad spectrum of tumors ranging from propulsion forcing the telescoping of this segment onto the lower one (Yang et al., 2005) . Indeed, the size of the tumors present in Apc 1638N/ þ :Ceacam1 À/À intussusceptions (17.2±2.5 mm 2 , Po0.05) was 21% more than that found in the Apc 1638N/ þ mice (14.1 ± 0.6 mm 2 ). The increase in intestinal obstruction in the compound mice also attests to the importance of CEACAM1 in tumor progression.
Extra-intestinal lesions are increased in
1638N/ þ mice also sustain tumor induction at extra-intestinal sites. For instance, colonic polyps were initially noticed in this model (Fodde et al., 1994) . Correspondingly, we found a significant increase in the number and grade of colon hyperplasias and adenomas in double heterozygotes (Po0.05) with a similar À/À jejunal and ileal segments of individual mice were subjected to SDSpolyacrylamide gel electrophoresis (PAGE) and immunoblotted with either an anti-pERK/anti-pAkt or total ERK/panAKT antibodies. Protein expression was computed from scanned immunoblots relative to either total Erk or pan-Akt levels. A.U. represents arbitrary units.
(E) Intestinal cells of WT and Ceacam1
À/À mice were labeled for Annexin V and evaluated by flow cytometry. Bar graph represents average geometric mean of flow cytometry curves (n ¼ 7 mice per group; *Po0.05).
À/À mice demonstrated a significant increase of approximately twofold in the number of desmoid tumors (Po0.01 relative to Apc 1638N/ þ and double heterozygotes, n ¼ 24; Figure 2e ). Desmoids represent a major cause of morbidity in the FAP patients due to local invasion (Smits et al., 1998) ; these were characterized pathologically as fibromatosis. These results suggest that CEACAM1 plays a role in dermal tumor progression initiated by APC mutations.
The Wnt signaling pathway is enhanced in Ceacam1 À/À mice The phenotypes observed in Ceacam1 À/À jejunum and ileum or in the intestinal tumor progression in Apc 1638N/ þ : Ceacam1 À/À mice suggest that absence of CEACAM1 created disruptions in major signaling pathways. We thus examined expression and activity levels of key intestinal proteins in the Wnt signaling pathway as it usually sustains major alterations in intestinal cancer. In fact, Jin et al. (2008) have recently shown by coimmunoprecipitation, glutathione-S-transferase (GST) pulldowns, mutational analyses, BiACore analyses and colocalization in breast cancer cells and human T lymphocytes that residues within the long cytoplasmic domain of human CEACAM1-L bind directly to the armadillo repeats of b-catenin. To verify expression or activity of key signaling proteins, cytosolic and nuclear fractions of total intestines were prepared ( Figure 3 ) and purity of these fractions was monitored by immunoblotting all intestinal samples with antibodies to HSP90 for cytosolic or laminB1 for nuclear fractions. As seen in Figures 3a and b , both the cytosolic and nuclear fractions were clean as judged by the exclusive expression of their respective marker. Neither total E-cadherin nor the Snail repressor expression levels were altered in Ceacam1 À/À intestines ( Figure 3a ; data not shown). However, a significant increase in cytosolic b-catenin 
Ceacam1 in intestinal tumor progression N Leung et al expression was noticed in Ceacam1 À/À intestines relative to its WT littermates (Po0.001, Figure 3a) , suggesting that b-catenin was stabilized and not degraded readily in the Ceacam1 À/À intestines. To confirm that CEACAM1-L indeed interacted with b-catenin in gastrointestinal cells, we first performed co-immunoprecipitation experiments using mouse CT26 and CT51 colon carcinoma cells stably expressing CEACAM1-L. We used mouse colon carcinoma cells instead of small intestinal cells as, to our knowledge, no mouse intestinal cell lines are available. As presented in Figure 4A , neither the CT26 nor the CT51 cells express CEACAM1 endogenously. However, they do transcribe and express the Apc mRNA (Supplementary Figure S1) . When the CT26 and CT51 CEACAM1-transfected cell lysates were subjected to co-immunoprecipitation with an anti-bcatenin antibody, CEACAM1-L readily associated with b-catenin, whereas CEACAM1-S did not bind to this protein. Colocalization studies also confirmed that CEACAM1-L and b-catenin were partners. Figure 4B, panel a) , as judged by the yellow overlay ( Figure 4B, panel c) . However, CT51 cells express E-cadherin (data not shown) that colocalizes with b-catenin at the cell surface. To verify that CEACAM1-L bound to b-catenin irrespective of its binding to E-cadherin, we therefore evaluated the CEACAM1-L-b-catenin colocalization in CT26 cells deficient in E-cadherin expression (Supplementary Figure S2 ). As observed previously, CEA-CAM1-L and b-catenin colocalized at cell-cell junctions as seen in the overlays ( Figure 4C , panels a-c), thus indicating that the b-catenin-CEACAM1-L interaction is independent of E-cadherin.
One of the hallmarks of colon and intestinal cancers is the nuclear expression of b-catenin. We thus examined whether jejunal and ileal nuclear fractions of Ceacam1 +/+ -/-n = 5 Figure 3 Immunoblotting of wild-type (WT) and carcinoembryonic antigen cell adhesion molecule 1 (Ceacam1) À/À jejunal and ileal cell lysates. Cytosolic and nuclear lysates were evaluated for their purity by blotting proteins from each individual mouse with antibodies to HSP90 (cytosolic marker) and laminB1 (nuclear marker). Representative immunoblots are shown. (a) Cytosolic proteins prepared from the indicated number (n) of WT and Ceacam1 À/À mice were subjected to SDS-polyacrylamide gel electrophoresis (PAGE) and immunoblotted with relevant antibodies, that is, E-cadherin, b-catenin and pGSK3b. (b) Nuclear fraction lysates were prepared to detect b-catenin, c-Myc, p21 and cyclin D1 proteins. Protein expression was computed from scanned immunoblots relative to either actin or laminB1 levels. (c) b-Catenin nuclear:cytosolic expression ratios were computed from scanned immunoblots of individual mice (n ¼ 5). b-Catenin nuclear expression is 1.45 fold more elevated in Ceacam1 À/À intestines than in control littermates. A.U. represent arbitrary units; *Po0.05 for pGSK-3b, nuclear b-catenin, c-Myc and cyclin D1; **Po0.001 for cytosolic b-catenin.
Ceacam1 in intestinal tumor progression N Leung et al expression was confirmed in immunoblots (Po0.05, Figure 3b ). We also calculated the nuclear:cytosolic ratio of b-catenin expression and found a trend toward higher expression in the nucleus in the Ceacam1 À/À mice (Figure 3c , P ¼ 0.12). This was paralleled by a slightly enhanced nuclear b-catenin expression in immunostained Ceacam1 À/À representative intestinal tissue sections relative to WT sections ( Figure 4D , black arrowheads). In line with this finding, a significant increase in cytosolic glycogen synthase kinase 3-b (GSK3-b) phosphorylation was observed in Ceacam1 Figure 5a ). A converse experiment where human CEACAM1 was silenced in Caco2 colon cancer cells was also performed. We chose the human Caco2 cell line, because all mouse colon cancer cell lines tested did not express CEACAM1-L endogenously whereas human Caco2 cells expressed both CEA and CEACAM1 (Figure 5b ). Two specific human CEACAM1 or negative control siRNAs as well as the TOPflash/ FOPflash vectors were introduced in Caco2 cells. Immunoblots, developed with the A20 mAb specific for human CEA and CEACAM1 (Figure 5b ), show reduced expression of human CEACAM1 by >90% under these experimental conditions, whereas CEA expression remained constant in Caco2 cells transfected with CEACAM1-specific siRNAs relative to untransfected cells. Reduced expression of human CEACAM1 significantly increased b-catenin/TCF transcriptional activity by approximately twofold relative to activity of scrambled siRNA controls or fourfold relative to untransfected cells (Figure 5c ). These results therefore indicate that expression of CEACAM1-L in gastrointestinal carcinoma cells significantly decreases b-catenin transcriptional activity whereas absence of CEACAM1 produces the reverse effect. c-Myc is one of the downstream targets of the Wnt signaling pathway and of the MAPK pathway (Hanahan and Weinberg, 2000) in intestinal epithelial cells (He et al., 1998; van de Wetering et al., 2002; Sansom et al., 2007) . Higher c-Myc expression was noticed in the Ceacam1 À/À jejunum and ileum in comparison to their control littermates (Po0.05, Figure 3b ). This was paralleled by a decrease in p21
Cip1 cyclin kinase inhibitor (Figure 3b) . Similarly, cyclin D1, another Wnt target, also showed significant enhanced expression (P ¼ 0.03, Figure 3b ).
Discussion
Analyses of CEACAM1-deficient mouse models confirmed CEACAM1's roles as a cell adhesion molecule (Obrink, 1997; Gray-Owen and Blumberg, 2006) , an inhibitory coreceptor in T lymphocytes (Nagaishi et al., 2006) , an angiogenic factor (Horst et al., 2006) and a signaling molecule affecting insulin clearance via the insulin receptor (Najjar, 2002) . CEACAM1 also Ceacam1 in intestinal tumor progression N Leung et al functions as a tumor suppressor in a number of cancers derived from the epithelium (Kunath et al., 1995; Hsieh et al., 1995; Nittka et al., 2004; Leung et al., 2006) . Unless triggered by a colon-specific carcinogen, Ceacam1 À/À mice do not develop colon tumors during their lifespan (Leung et al., 2006) . As CEACAM1 is downregulated early in the development of human colon tumors (Nollau et al., 1997; Nittka et al., 2004) and APC is considered one of the first genes mutated in intestinal cancer , we questioned whether CEACAM1 influenced APC signaling pathways and enhanced the progression of intestinal tumors developing on the Apc 1638N/ þ mutant background. We first examined changes in the normal adult Ceacam1 À/À intestine relative to proliferation, migration and apoptosis. Contrary to results observed with the Ceacam1
À/À and WT intestinal crypts proliferated at the same rate. This was confirmed by similar Erk activity. In addition, Ceacam1
À/À and WT enterocytes exhibited similar migration rates. This result suggests that CEACAM1 is regulating other functions in intestine. On the other hand, Ceacam1
À/À enterocytes, in parallel with colonocytes (Leung et al., 2006) , demonstrated a two to threefold decrease in apoptosis. This reemphasizes the role of CEACAM1 as a positive regulator of this process, as was previously shown in human HT-29 cells and CRCs (Nittka et al., 2004) . However, levels of phosphorylated Akt were not significantly different in CEACAM1-null intestines relative to controls, implicating maintenance of apoptosis through other signaling pathways. Inhibition of apoptosis in the absence of CEACAM1 is most likely the greatest factor contributing to the tumor growth observed.
Although no increase in normal intestinal cell proliferation was observed, compound Apc 1638N/ þ : Ceacam1 À/À mice showed a slight but significant enhancement of intestinal tumor multiplicity relative to the Apc 1638N/ þ littermates. The effect is more muted than that observed in carcinogen-induced colon tumors (Leung et al., 2006) , but azoxymethane-elicited tumorigenesis produces mutations in a significant number of genes (Vivona et al., 1993) . Additionally, we showed that the second Apc allele was generally lost in tumors whereas expression from the remaining Ceacam1 allele appears unaffected (data not shown). Importantly however, the Apc 1638N/ þ :Ceacam1
-derived tumors progressed to a more advanced stage as defined by the larger tumor sizes (>30%) and a higher ratio of carcinomas:adenomas in the compound mice versus their Apc 1638N/ þ littermates, suggesting that both proliferation and migration of intestinal tumor cells were influenced by the CEACAM1 deletion in the Apc mutated background. In addition to intestinal tumor development, CEACAM1 deletion also increased the formation of intussusceptions (fivefold enhancement) and desmoids lesions. Intussusceptions are uncommon in human patients and generally cause intestinal blockage due to a pathologic lesion that is most often malignant (Azar and Berger, 1997) . The development of intussusceptions in Apc 1638N/ þ :Ceacam1 À/À mice may be linked to adipose deposits surrounding large tumors within the intussusceptions. Remarkably, loss of CEACAM1 expression affected the normal Wnt signaling pathway in the intestines. Jin et al. (2008) have recently shown that CEACAM1-L directly associates with the b-catenin armadillo repeats. We have confirmed this finding and shown that CEACAM1-L binds to and colocalizes with b-catenin in colon cancer cells. Second, b-catenin nuclear expression is slightly enhanced in jejunal and ileal intestinal segments. As well, TCF/Lef transcriptional activity is significantly augmented in CT51 cells relative to those transfected with CEACAM1-L and in Caco2 cells having sustained a decrease of CEACAM1 expression. This is further supported by a significant increase in the GSK3-b phosphorylation in the Ceacam1 À/À intestines, rendering this kinase inactive. Unphosphorylated b-catenin cannot be appropriately targeted for degradation in the destruction complex, resulting in increased cytosolic b-catenin expression. Notably, GSK3-b inhibition through its phosphorylation in vivo is dependent upon insulin-mediated activation of PI3K/Akt pathways (Patel et al., 2004) . CEACAM1 regulates insulin receptor endocytosis and insulin clearance from the liver and inactivation of GSK3-b activity is likely a consequence of dysregulated insulin receptor signaling in these mice (Poy et al., 2002b) . Furthermore,
Ceacam1
À/À intestines demonstrated a significant increase of c-Myc and cyclin D1 and a decrease p21 Cip1 expression, all well-known Tcf-LEF targets (van de Wetering et al., 2002) . These results suggest that CEACAM1 and APC are both contributing to the Wnt signaling pathway via their interactions with a common partner, that is, b-catenin. The results also highlight that in vivo CEACAM1 downregulation in intestinal tissue results in decreased apoptosis, rendering these cells sensitive to accumulation of genetic mutations of relevant genes including APC. It has recently been shown that increased Wnt signaling contributes to chromosomal instability in APC or b-catenin mutant cells (Aoki et al., 2007) . Ultimately, dysregulation of Wnt signaling in Ceacam1 À/À intestines may also enhance genomic instability and contribute to tumor progression.
Materials and methods

Animal models
C57Bl6/129 Ceacam1 À/À lines 2D2 and 11H11 (Leung et al., 2006; backcross 6) were mated to C57Bl6/129P (backcross 8) Apc 1638N/ þ mice (Fodde et al., 1994; NCI Frederick Mouse Repository) 
and Apc 1638N/ þ mice were genotyped as described (Fodde et al., 1994; Leung et al., 2006) . Experiments were performed on animals having reached a minimum of backcross 10. Skin, small intestine and colon of 6-to 7-month-old mice were examined at necropsy and lesions/tumors were counted, measured and fixed in 10% buffered formalin or frozen in optimal cutting temperature (OCT) medium. Tumors were independently graded by two clinical pathologists. All animal experiments were carried out according to protocols approved by the Animal Ethics Committee of McGill University. In vivo BrdU-labeled proliferation assays In vivo intestinal cell proliferation assays and their migration up the villi were performed with BrdU labeling (Sigma, St Louis, MO, USA; Velcich et al., 2002) on six sibling pairs of 6-month-old Ceacam1 À/À and WT mice for proliferation or seven sibling pairs for migration measurements. Mice were killed 2-24 h post-BrdU injections and tissues processed as described (Leung et al., 2006) .
Immunohistochemistry, immunofluorescence and flow cytometry Tissue sections were stained using anti-BrdU (1:1000; Sigma) and anti-Ki67 (1:50; Dako, Mississauga, Ontario, Canada) antibodies (Leung et al., 2006) . PAS staining was used for mucin detection. Mouse CT26 and CT51 colon carcinoma cells stably expressing CEACAM1-L have previously been described (Kunath et al., 1995; Turbide et al., 1997) . For immunofluorescence, sections were treated with antibodies to b-catenin (1:500) and CEACAM1 (CC1, 1:1000; Dveksler et al., 1993) and labeled with fluorescein isothyocyanate-and Cy3-conjugated antibodies (Jackson Labs, West Grove, PA, USA). Sections were mounted in Dako Cytomation mounting medium and analysed on a Zeiss LSM 5 Pascal using Axiovert 200 confocal microscope. Jejunal and ileal single cell suspensions were obtained by incubating the tissue in 0.5 mM DTT, 1 mM EDTA in phosphate buffered saline (PBS) for 15 min at 37 1C with occasional shaking. Recovered cells were stained with Annexin V antibodies as described (Leung et al., 2006) . b-catenin antibody (1:1000; BD Biosciences Pharmingen, San Diego, CA, USA) immunostaining of paraffin-embedded intestinal sections was also performed as described in (Leung et al., 2006) . Briefly, 5 mm thick sections were deparaffinized and rehydrated, heated in the microwave for 15 min in sodium citrate pH 6 buffer, blocked in 5% bovine serum albumin, 5% normal goat serum, incubated with primary antibody for 1 h at room temperature, followed by three washes in PBS, incubated with anti-rabbit-horseradish peroxidase conjugated antibody for 1 h, followed by three washes in PBS, incubated with rabbit PAP antibody for 1 h, followed by three washes in PBS. Color development was carried out with 3,3 0 -diaminobenzidine (Sigma). Slides were dehydrated and mounted with Permount (Fisher, Montreal, Quebec, Canada).
Immunoprecipitation and immunoblotting analyses
Jejunal and ileal epithelial cells were collected by scraping of the intestinal mucosa and homogenized in lysis buffer (10 mM TrisCl pH 8.0, 2 mM EDTA, 1% NP-40, 1 Â Roche protease inhibitors). Nuclear extracts were obtained as previously described (Leung et al., 2006) . 50-100 mg of protein lysate was loaded on 10-12% SDS polyacrylamide gels. Immunoblots were incubated with antibodies to p21
Cip1 and c-Myc (1:1000, Upstate Biotech, Charlottesville, VA, USA), E-cadherin (1:500; Transduction Laboratories, Lexington, KN, USA), p-Akt (1:1000,Thr308 and Ser473) and pan Akt, p-Erk and pan Erk, b-catenin, pGSK3-b (1:1000; all from Cell Signaling, Danvers, MA, USA), cyclin D1 (1:1000; Santa Cruz, Santa Cruz, CA, USA), laminB1 (1:1000; Sigma), HSP90 (1:1000; Cell Signalling, Danvers, MA, USA) and actin (1:2000; Sigma). Signals were detected using the Western Lightning Chemiluminescent reagent plus (Perkin Elmer, Boston, MA, USA). Expression levels of various proteins were computed from scanned immunoblots. CT26 and CT51 total cell lysates prepared in the same buffer as above were subjected to immunoprecipitations with either the anti-bcatenin Ab or preimmune serum and the complexes were separated by SDS-polyacrylamide gel electrophoresis (PAGE) and blotted with the anti-CEACAM1 Ab (3759). Cell lysates from human Caco2 colon carcinoma cells transfected with anti-CEACAM siRNAs or scrambled siRNA were prepared and after SDS-PAGE, proteins were immunoblotted with an A20 mAb specific for human CEA and human CEACAM1.
Reverse transcription-PCR on CT51 cells RNA was isolated from CT51 cells using Trizol reagent (Invitrogen, Burlington, Ontario, Canada) . cDNA was synthesized with Superscript II enzyme (Invitrogen). Subsequent PCR was performed using the following primers: for the Apc gene forward primer 5 0 -AAACGGCATGATATTGCACGCTCC and reverse primer 5 0 -TGTTTGCTGTGTTCACGCTTCC AG, for the Ceacam1 gene forward 5 0 -TACATGAAATYGC ACAGTCGC and reverse 5 0 -CTGCCCCTGGCGCTTG GAA, for the G3PDH gene forward 5 0 -CCATGGAGA AGGCTGGGG and reverse 5 0 -CAAAGTTGTCATGGATG ACC. The controls used were genomic DNA extracted from tails of Apc þ / þ and þ /À and Ceacam1
, and À/À mice.
Luciferase assays
Mouse CT51 colon carcinoma cells (5 Â 10 4 ), expressing or not CEACAM1-L (Kunath et al., 1995) were transfected with 2 mg of either the TOPflash or FOPflash plasmids (Upstate Biotech) and 200 ng of the pRSV-LacZ plasmid using Lipofectamine 2000 (Invitrogen). At 48-72 h after transfection, cells were lysed and analysed for light emission on a Lumat LB9507 (Berthold Technology, Bad Wilbad, Germany) luminometer (Kobrossy et al., 2006) . b-galactosidase assays were performed as described (Kobrossy et al., 2006) ).
siRNA-mediated silencing of human CEACAM1
Previous literature has demonstrated efficient knock down of human CEACAM1 (Hokari et al., 2007; Liu et al., 2007) . Small interfering RNA duplexes designed to target hCEA-CAM1 were synthesized by Ambion as follows: for siRNA1 5 0 -UAACUCAGUCACUGGCUGCAA (sense) and 5 0 -GCA GCCAGUGACUGAGUUAAA (antisense); for siRNA2 5 0 -CCGUCAAAUUGUAGGAUAUAA (sense), and 5 0 -AU AUCCUACAAUUUGACGGAA (antisense). Caco2 cells were transfected using Lipofectamine 2000 reagent (Invitrogen) with siRNAs. 24 h later, transfection complexes were removed and cells were retransfected with TOPflash, FOPflash and b-galactosidase vectors using Fugene 6 reagent (Roche, Laval, Quebec, Canada). After 48 h, cells were harvested for luciferase and b-galactosidase assays, as well as immunoblotting analyses.
Statistical analysis
Data were analysed using the Student's t-test. P-values were considered significant if o0.05. Standard errors (s.e.) are represented in the bar graphs.
